Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2009

View Archived Issues

EMEA grants orphan drug designation for pixantrone

EMEA recommends withdrawal of benfluorex from the market in E.U.

Sanofia-aventis withdraws MAA for Sliwens for insomnia

FDA extends PDUFA action date for Cephalon's sNDA for Nuvigil

Novartis to acquire Corthera and exclusive worldwide rights to relaxin

Shire submits BLA to the FDA for Replagal, updates Gaucher disease therapy

Encouraging phase I data reported for TRU-016 in relapsed/refractory CLL

Clinical data on pomalidomide in myelofibrosis patients disclosed at ASH meeting

Everolimus shows clinical activity in Waldenstrom's macroglobulinemia and myelofibrosis

Phase I data reported for PD-0332991 plus letrozole in advanced breast cancer

Lactobacillus rhamnosus CGMCC 1.3724 may prevent atopic dermatitis onset

Roche discloses CPT-2 inhibitors for the treatment of type 2 diabetes

Takeda describes tachykinin antagonists for IBS therapy

Wellstat Therapeutics developing URAT1 inhibitors for the treatment of gout

Vitae Pharmaceuticals and Boehringer Ingelheim claim novel antiobesity agents

GlaxoSmithKline presents S1P1 receptor agonists as antiarthritic agents

Arena submits NDA to FDA for lorcaserin for weight management

Biovitrum sells leptin modulator program to AstraZeneca

ImmuneRegen reports efficacy for its new adjuvant of a preventive cancer vaccine

Ligand obtains positive regulatory opinion in Europe for Revolade

Mylan receives tentative FDA approval for efavirenz tablets

PolyMedix completes main portions of phase Ib PMX-30063 study

Resverlogix initiates phase II atherosclerosis clinical trial

Merck to discontinue development of MK-1903 under atherosclerosis program with Arena

Synta initiates phase II study of STA-9090 in metastatic or unresectable GIST

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
US lawmakers demand that Kennedy be held accountable
BioWorld
As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
Heartbeam wins appeal, gains FDA clearance
BioWorld MedTech
Management is beaming with delight at Heartbeam Inc. as the company's appeal strategy paid off with U.S. FDA clearance for its synthetic 12-lead electrocardiogram...